AU Wells, DM Hansell, MB Rubens, P Cullinan, PL Haslam, CM Black and RM Du Bois
Department of Thoracic Medicine, Radiology, Royal Brompton National Heart and Lung Hospital, London, United Kingdom.

Fibrosing alveolitis in systemic sclerosis is histologically identical to lone cryptogenic fibrosing alveolitis (CFA) (idiopathic pulmonary fibrosis). The inflammatory cell content of bronchoalveolar lavage (BAL) samples has been used as a guide to prognosis and treatment in CFA. In this study, the relationship was explored between BAL findings and the extent and pattern of disease within the lavaged lobe, as judged by thin-section computed tomography (CT), in systemic sclerosis. Thirty-eight nonsmoking patients were studied; none had been treated with corticosteroids or immunosuppressive agents, and 11 had no evidence of fibrosing alveolitis on CT. BAL neutrophils were markedly increased in association with extensive disease on CT compared with less extensive disease (p < 0.001) and normal appearances (p < 0.001); the extent of a reticular pattern on CT (denoting fibrosis) correlated with the neutrophil percentage count (p < 0.005) and total neutrophil count/ml (p < 0.01). BAL eosinophils were increased in less extensive as well as in extensive disease when compared with lobes with a normal CT appearance (p < 0.01); eosinophil percentage counts but not total eosinophil counts/ml correlated with the extent of a ground-glass pattern on CT (through to denote inflammation) (p < 0.05). These findings indicate that in systemic sclerosis a BAL neutrophilia is generally associated with extensive fibrotic disease, whereas a BAL eosinophilia is often seen in less advanced disease, particularly when CT appearances suggest lung inflammation.

This article has been cited by other articles:

				A. Scheja, K. Larsen, L. Todorova, E. Tufvesson, M. Wildt, A. Akesson, L. Hansson, S. Ellis, and G. Westergren Thorsson BALF-derived fibroblasts differ from biopsy-derived fibroblasts in systemic sclerosis Eur. Respir. J., March 1, 2007; 29(3): 446 - 452. [Abstract] [Full Text] [PDF]

				M R Hussein, H I Hassan, E R M Hofny, M Elkholy, N A Fatehy, A E A Abd Elmoniem, A M Ezz El-Din, O A Afifi, and H G Rashed Alterations of mononuclear inflammatory cells, CD4/CD8+ T cells, interleukin 1{beta}, and tumour necrosis factor {alpha} in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis J. Clin. Pathol., February 1, 2005; 58(2): 178 - 184. [Abstract] [Full Text] [PDF]

				S. R. Desai, S. Veeraraghavan, D. M. Hansell, A. Nikolakopolou, N. S. L. Goh, A. G. Nicholson, T. V. Colby, C. P. Denton, C. M. Black, R. M. du Bois, et al. CT Features of Lung Disease in Patients with Systemic Sclerosis: Comparison with Idiopathic Pulmonary Fibrosis and Nonspecific Interstitial Pneumonia Radiology, August 1, 2004; 232(2): 560 - 567. [Abstract] [Full Text] [PDF]

				D. Bouros, A. U. Wells, A. G. Nicholson, T. V. Colby, V. Polychronopoulos, P. Pantelidis, P. L. Haslam, D. A. Vassilakis, C. M. Black, and R. M. du Bois Histopathologic Subsets of Fibrosing Alveolitis in Patients with Systemic Sclerosis and Their Relationship to Outcome Am. J. Respir. Crit. Care Med., June 15, 2002; 165(12): 1581 - 1586. [Abstract] [Full Text] [PDF]

				American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias . This Joint Statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS Board of Directors, June 2001 and by The ERS Executive Committee, June 2001 Am. J. Respir. Crit. Care Med., January 15, 2002; 165(2): 277 - 304. [Full Text] [PDF]

				J Fujita, T Yoshinouchi, Y Ohtsuki, M Tokuda, Y Yang, I Yamadori, S Bandoh, T Ishida, J Takahara, and R Ueda Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis Ann Rheum Dis, March 1, 2001; 60(3): 281 - 283. [Abstract] [Full Text] [PDF]

				B. White, W. C. Moore, F. M. Wigley, H. Q. Xiao, and R. A. Wise Cyclophosphamide Is Associated with Pulmonary Function and Survival Benefit in Patients with Scleroderma and Alveolitis Ann Intern Med, June 20, 2000; 132(12): 947 - 954. [Abstract] [Full Text] [PDF]

				J.-i. Ashitani, H. Mukae, H. Taniguchi, T. Ihi, J.-i. Kadota, S. Kohno, and S. Matsukura Granulocyte-colony stimulating factor levels in bronchoalveolar lavage fluid from patients with idiopathic pulmonary fibrosis Thorax, November 1, 1999; 54(11): 1015 - 1020. [Abstract] [Full Text]

				C. Witt, A. C Borges, M. John, I. Fietze, G. Baumann, and A. Krause Pulmonary involvement in diffuse cutaneous systemic sclerosis: broncheoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis Ann Rheum Dis, October 1, 1999; 58(10): 635 - 640. [Abstract] [Full Text]

				D. M Mitchell and A. Woodcock Introduction Thorax, August 1, 1999; 54(90002): S1 - 1. [PDF]

				A. Wells Clinical usefulness of high resolution computed tomography in cryptogenic fibrosing alveolitis Thorax, December 1, 1998; 53(12): 1080 - 1087. [Full Text]

				A. U. WELLS, D. M. HANSELL, P. L. HASLAM, M. B. RUBENS, J. CAILES, C. M. BLACK, and R. M. du BOIS Bronchoalveolar Lavage Cellularity . Lone Cryptogenic Fibrosing Alveolitis Compared with the Fibrosing Alveolitis of Systemic Sclerosis Am. J. Respir. Crit. Care Med., May 1, 1997; 157(5): 1474 - 1482. [Abstract] [Full Text]

				B. T. SOCIETY and S. O. C. COMMITTEE The Diagnosis, Assessment and Treatment of Diffuse Parenchymal Lung Disease in Adults---British Thoracic Society recommendations Thorax, April 1, 1990; 54(90001): 1S - 28. [Full Text]